{
  "source": "PA-Notification-Regranex.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1087-12\nProgram Prior Authorization/Notification\nMedication Regranex® (becaplermin gel)\nP&T Approval Date 1/2004, 5/2006, 11/2007,12/2008, 12/2009, 9/2010, 9/2011, 6/2012,\n8/2012, 8/2013, 8/2014, 7/2015, 7/2016, 7/2017, 8/2018, 8/2019, 9/2020,\n9/2021, 11/2022, 1/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nRegranex is indicated for the treatment of lower extremity diabetic neuropathic ulcers that\nextend into the subcutaneous tissue, or beyond, and have an adequate blood supply. Regranex\nshould be used as an adjunct to, and not a substitute for, good ulcer care practices including\ninitial sharp debridement, pressure relief and infection control. The efficacy of Regranex gel has\nnot been established for the treatment of pressure ulcers or venous stasis ulcers. If a member has\na prescription for a diabetic medication within the last 180 days of claim’s history, the\nprescription for Regranex will automatically process.\n2. Coverage Criteriaa:\nA. Authorization\n1. Regranex will be approved based on both of the following criteria:\na. Patient has a lower extremity diabetic neuropathic ulcer\n-AND-\nb. Treatment will be given in combination with ulcer wound care (e.g., debridement,\ninfection control and/or pressure relief)\nAuthorization will be issued for 6 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Regranex [package insert]. Fort Worth, Tx: Smith & Nephew, Inc; Aug",
    "ed approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Regranex [package insert]. Fort Worth, Tx: Smith & Nephew, Inc; August 2019.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Regranex\nChange Control\nDate Change\n8/2014 Annual review. Reference updated.\n7/2015 Annual review. Revisions to formatting. Increased authorization period\nto six months.\n7/2016 Annual review. Reference updated.\n7/2017 Annual review. Reference updated.\n8/2018 Annual review. No changes.\n8/2019 Annual review. Reference updated.\n9/2020 Annual review. References updated.\n9/2021 Annual review. No changes.\n11/2022 Annual review. Added state mandate footnote.\n1/2024 Annual review. No changes.\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}